Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gastrointestinal-mediated hypoglycemic effects of imeglimin assessed by PET/MR enterography
jRCTs051220192Active, not recruiting
- Start
- May 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label trial of imeglimin in type 2 diabetes mellitus (T2DM) (2 arms). Primary endpoint: FDG excretion per hour into the intestinal lumen. Started May 2023; status: active, not recruiting.
02
Drugs
imeglimin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on jRCTs051220192.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs051220192.